| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 255 | 2021 |
| Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy M Cecconi, D Piovani, E Brunetta, A Aghemo, M Greco, M Ciccarelli, ... Journal of clinical medicine 9 (5), 1548, 2020 | 213 | 2020 |
| Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection E Brunetta, M Fogli, S Varchetta, L Bozzo, KL Hudspeth, E Marcenaro, ... Aids 24 (1), 27-34, 2010 | 160 | 2010 |
| The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer–cell subsets associated with high levels of HIV-1 viremia E Brunetta, M Fogli, S Varchetta, L Bozzo, KL Hudspeth, E Marcenaro, ... Blood, The Journal of the American Society of Hematology 114 (18), 3822-3830, 2009 | 152 | 2009 |
| HIV-1 Vpr Triggers Natural Killer Cell–Mediated Lysis of Infected Cells through Activation of the ATR-Mediated DNA Damage Response J Ward, Z Davis, J DeHart, E Zimmerman, A Bosque, E Brunetta, D Mavilio, ... PLoS pathogens 5 (10), e1000613, 2009 | 152 | 2009 |
| Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 E Brunetta, M Folci, B Bottazzi, M De Santis, G Gritti, A Protti, SN Mapelli, ... Nature immunology 22 (1), 19-24, 2021 | 124 | 2021 |
| Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes E Brunetta, KL Hudspeth, D Mavilio Journal of leukocyte biology 88 (6), 1119-1130, 2010 | 114 | 2010 |
| Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals M Fogli, D Mavilio, E Brunetta, S Varchetta, K Ata, G Roby, C Kovacs, ... PLoS pathogens 4 (7), e1000101, 2008 | 111 | 2008 |
| The X chromosome and the sex ratio of autoimmunity C Selmi, E Brunetta, MG Raimondo, PL Meroni Autoimmunity reviews 11 (6-7), A531-A537, 2012 | 100 | 2012 |
| Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients LM Canziani, S Trovati, E Brunetta, A Testa, M De Santis, E Bombardieri, ... Journal of autoimmunity 114, 102511, 2020 | 89 | 2020 |
| Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real‐life setting M Gatto, F Saccon, M Zen, F Regola, M Fredi, L Andreoli, A Tincani, ... Arthritis & Rheumatology 72 (8), 1314-1324, 2020 | 88 | 2020 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 80 | 2023 |
| Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes S Varchetta, E Brunetta, A Roberto, J Mikulak, KL Hudspeth, MU Mondelli, ... Public Library of Science 7 (9), e45821, 2012 | 67 | 2012 |
| COVID-19 digestive system involvement and clinical outcomes in a large academic hospital in Milan, Italy A Aghemo, D Piovani, TL Parigi, E Brunetta, N Pugliese, E Vespa, ... Clinical Gastroenterology and Hepatology 18 (10), 2366-2368. e3, 2020 | 65 | 2020 |
| Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis I Dell'Aica, R Niero, F Piazza, A Cabrelle, L Sartor, C Colalto, E Brunetta, ... Journal of Pharmacology and Experimental Therapeutics 321 (2), 492-500, 2007 | 63 | 2007 |
| The brain-gut axis: psychological functioning and inflammatory bowel diseases S Peppas, C Pansieri, D Piovani, S Danese, L Peyrin-Biroulet, ... Journal of clinical medicine 10 (3), 377, 2021 | 60 | 2021 |
| Cutting edge: biomarkers for chronic spontaneous urticaria M Folci, E Heffler, GW Canonica, R Furlan, E Brunetta Journal of Immunology Research 2018, 2018 | 51 | 2018 |
| 3-(2, 4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2, 5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of … C Gurrieri, F Piazza, M Gnoato, B Montini, L Biasutto, C Gattazzo, ... Journal of Pharmacology and Experimental Therapeutics 332 (3), 785-794, 2010 | 49 | 2010 |
| Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease A Cabrelle, I Dell’Aica, L Melchiori, S Carraro, E Brunetta, R Niero, ... Journal of Leucocyte Biology 83 (1), 212-219, 2008 | 46 | 2008 |
| Cytokines, chemokines and other biomolecular markers in sarcoidosis. C Gurrieri, M Bortoli, E Brunetta, F Piazza, C Agostini Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of …, 2005 | 45 | 2005 |
